Radiopharm Theranostics Ltd (RADX) Non-Current Assets (2024 - 2026)

Radiopharm Theranostics (RADX) has reported Non-Current Assets for 3 consecutive years, with $271028.9 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 9.24% year-over-year to $271028.9 in Q2 2026; TTM through Jun 2026 was $271028.9, a 9.24% decrease from a year earlier, with the FY2026 full-year figure at $259492.6, down 99.44% from the prior year.
• Non-Current Assets was $271028.9 for Q2 2026 at Radiopharm Theranostics, down from $298620.5 in the prior quarter.
• Over five years, Non-Current Assets peaked at $48.1 million in Q4 2024 and troughed at $271028.9 in Q2 2026.
• A 3-year average of $12.2 million and a median of $311391.0 in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets slipped 7.88% in 2025 and retreated 9.24% in 2026, its largest moves.
• Over 3 years, Non-Current Assets stood at $48.1 million in 2024, then plunged by 99.38% to $298620.5 in 2025, then decreased by 9.24% to $271028.9 in 2026.
• The last three Non-Current Assets figures came in at $271028.9 (Q2 2026), $298620.5 (Q2 2025), and $48.1 million (Q4 2024), per Business Quant data.